Eton Pharmaceuticals has an esteemed board of directors who are widely recognized for their experience, leadership and achievements in the pharmaceutical and health care industries. These accomplished executives and entrepreneurs have helped guide the rapid expansion of Eton’s pipeline. They share our passion for innovation and the advancement of medicine.

Sean Brynjelsen, Chief Executive Officer

Chief Executive Officer & Director

Sean Brynjelsen brings to the company more than 20 years of pharmaceutical industry experience, with particular expertise in business development and product development. Prior to joining Eton, Mr. Brynjelsen was Executive Vice President of Business Development at Sagent Pharmaceuticals, a generic injectable company that was acquired by Nichi-Iko Pharmaceuticals. Prior to Sagent, he was Senior Vice President of Global Business Development at Akorn Inc, a pharmaceutical company specializing in ophthalmic and injectable products.

Early in his career, Mr. Brynjelsen spent more than 10 years in product development focused on injectable pharmaceuticals at Baxter, Abbott, and Hospira. He has an MBA from the University of Notre Dame, and a Masters of Science in Chemistry and a Bachelor of Science in Chemistry from the University of Illinois.

Dr. Norbert Riedel, Chairman of the Board
Dr. Norbert Riedel is the CEO of Aptinyx.

Prior to joining Aptinyx, Dr. Riedel was president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Innovation Organization.

Mark Baum
Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals, a commercial stage pharmaceutical company focused on providing patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets.  Mr. Baum is also a founder and board member of Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals.  Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region.  Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, Mr. Baum made more than 200 investments into more than 40 private and public companies.  In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business.  Mr. Baum’s advocacy for drug pricing and accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera.  Mr. Baum is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law
Charles Casamento

Charles J. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007.

He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.’s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr. Casamento also serves on the Board of Directors of Relmada Therapeutics, AzurRx BioPharma and International Stem Cell Corp.

He is Chairman of the Board at Relmada. During his career he has sat on the boards of twelve public companies and has also been a Director and Vice Chairman of The Catholic Medical Missions Board, a large not for profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor’s degree in Pharmacy from Fordham University and an M.B.A. from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey.

Paul V. Maier

Audit Committee Chairman, Eton Pharmaceutical

Paul V. Maier currently serves as a financial advisor to the life science industry.

Mr. Maier is the former CFO of Sequenom, Inc. and Ligand Pharmaceuticals Inc. and has over 25 years experience as a senior executive in biotechnology and specialty pharmaceutical companies.  Mr. Maier has served on the boards of eight companies and currently serves as Audit Committee Chair on four public life science companies.  Mr. Maier received an M.B.A from Harvard Business School and a B.S. from Pennsylvania State University.  Mr. Maier is also an Executive Partner at the College of William & Mary Mason School of Business.

Eton Pharmaceuticals has an esteemed board of directors who are widely recognized for their experience, leadership and achievements in the pharmaceutical and health care industries. These accomplished executives and entrepreneurs have helped guide the rapid expansion of Eton’s pipeline. They share our passion for innovation and the advancement of medicine.

Sean Brynjelsen, Chief Executive Officer

Chief Executive Officer & Director

Sean Brynjelsen brings to the company more than 20 years of pharmaceutical industry experience, with particular expertise in business development and product development. Prior to joining Eton, Mr. Brynjelsen was Executive Vice President of Business Development at Sagent Pharmaceuticals, a generic injectable company that was acquired by Nichi-Iko Pharmaceuticals. Prior to Sagent, he was Senior Vice President of Global Business Development at Akorn Inc, a pharmaceutical company specializing in ophthalmic and injectable products.

Early in his career, Mr. Brynjelsen spent more than 10 years in product development focused on injectable pharmaceuticals at Baxter, Abbott, and Hospira. He has an MBA from the University of Notre Dame, and a Masters of Science in Chemistry and a Bachelor of Science in Chemistry from the University of Illinois.

Dr. Norbert Riedel, Chairman of the Board
Dr. Norbert Riedel is the CEO of Aptinyx.

Prior to joining Aptinyx, Dr. Riedel was president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Innovation Organization.

Mark Baum

Chairman of Eton Pharmaceutical

Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals, a commercial stage pharmaceutical company focused on providing patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets.  Mr. Baum is also a founder and board member of Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals.  Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region.  Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, Mr. Baum made more than 200 investments into more than 40 private and public companies.  In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business.  Mr. Baum’s advocacy for drug pricing and accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera.  Mr. Baum is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law

Charles Casamento

Charles J. Casamento is currently Executive Director and Principal of The Sage Group, a healthcare advisory group specializing in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies, since 2007.

He was the president and CEO of Osteologix, Inc., a public biopharmaceutical company developing products for treating osteoporosis, from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. which was subsequently acquired by Mallinckrodt. Mr. Casamento formerly served as RiboGene, Inc.’s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. He was co-founder, president and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company, from 1989 until 1993. Indevus was eventually acquired by Endo. Mr. Casamento has also held senior management positions at Genzyme Corporation, where he was senior vice president, pharmaceuticals and biochemicals; American Hospital Supply, where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Sandoz Inc. Mr. Casamento also serves on the Board of Directors of Relmada Therapeutics, AzurRx BioPharma and International Stem Cell Corp.

He is Chairman of the Board at Relmada. During his career he has sat on the boards of twelve public companies and has also been a Director and Vice Chairman of The Catholic Medical Missions Board, a large not for profit organization providing health care services to third world countries. He has served as a guest lecturer at Fordham University and is on the Science Council of Fordham University. He holds a bachelor’s degree in Pharmacy from Fordham University and an M.B.A. from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey.

Paul V. Maier

Audit Committee Chairman, Eton Pharmaceutical

Paul V. Maier currently serves as a financial advisor to the life science industry.

Mr. Maier is the former CFO of Sequenom, Inc. and Ligand Pharmaceuticals Inc. and has over 25 years experience as a senior executive in biotechnology and specialty pharmaceutical companies.  Mr. Maier has served on the boards of eight companies and currently serves as Audit Committee Chair on four public life science companies.  Mr. Maier received an M.B.A from Harvard Business School and a B.S. from Pennsylvania State University.  Mr. Maier is also an Executive Partner at the College of William & Mary Mason School of Business.